Document is current
Any future updates will be listed below
-
Authors
Anandh, Urmila https://orcid.org/0000-0003-3298-8642
Anders, Hans-Joachim
Bacchetta, Justine https://orcid.org/0000-0002-0578-2529
Johnson, David W https://orcid.org/0000-0001-5491-3460
Luyckx, Valerie https://orcid.org/0000-0001-7066-8135
Remuzzi, Giuseppe https://orcid.org/0000-0002-6194-3446
Rodriguez-Iturbe, Bernardo https://orcid.org/0000-0002-5284-2440
Susztak, Katalin https://orcid.org/0000-0002-1005-3726
Tuttle, Katherine https://orcid.org/0000-0002-2235-0103
Yanagita, Motoko https://orcid.org/0000-0002-0339-9008
- License Information
-
More Information
Article History
Accepted: 31 July 2025
First Online: 19 September 2025
Competing interests
: H.-J.A. has received lecture and consultancy fees from GSL, Novartis, AstraZeneca, Roche, Bayer, Boehringer-Ingelheim, SOBI, Otsuka and CSL Vifor. He receives payments for his role as Editor-in-Chief of Nephrology Dialysis Transplantation. Within the past 3 years, J.B. has received consultant and speaker fees from Kyowa Kirin, Alnylam, Novonordisk, Biocodex, Amgen, Alexion, Viatris and Amolyt, and research grants from Kyowa Kirin. D.W.J. has received consultancy fees, research grants, speaker’s honoraria and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from AstraZeneca, Bayer, and AWAK, speaker’s honoraria from ONO and Boehringer Ingelheim & Lilly, and travel sponsorships from Ono and Amgen. He is a current recipient of an Australian National Health and Medical Research Council Leadership Investigator Grant (APP1194485). K.S. has consulted for Otsuka, Pfizer, Vertex and ProKidney therapeutics and is a founder of Tarna Therapeutics. The Susztak laboratory receives funding from Regeneron, Genentech, Novartis, Boehringer Ingelheim, Gilead, Novo Nordisk, GSK and Calico. K.T. has received grants from Bayer and Travere for investigator-initiated research paid to her institution, has consulted for Eli Lilly and Company, Boehringer Ingelheim, Bayer, AstraZeneca, Novo Nordisk and ProKidney. M.Y. received research grants from Mitsubishi Tanabe Pharma and Boehringer Ingelheim, lecture honoraria from Astellas, AstraZeneca, Kyowa Kirin, Mitsubishi Tanabe Pharma Corporation and Chugai Pharmaceuticals, and is on the advisory board of AstraZeneca and Novartis. The other authors declare no competing interests.
